Abstract
The antimicrobial peptide LL-37 is the only cathelicidin that has been described in humans. LL-37 exerts chemotactic, immunomodulatory and angiogenic effects; activities that are mediated through binding to the formyl peptide receptor like (FPRL)-1 receptor. Agonistic ligation of FPRL-1 can also induce down-regulation of HIV-1 chemokine receptors and reduce susceptibility to HIV-1 infection in vitro. Therefore, we have evaluated the capacity of LL-37 to inhibit HIV-1 infection in vitro. Here we demonstrate that LL-37 inhibits HIV-1 replication in PBMC, including primary CD4+ T cells. This inhibition was readily reproduced using various HIV-1 isolates without detectable changes in the target cell expression of HIV-1 chemokine receptors. Accordingly, the HIV-1 inhibitory effect was shown to be independent of FPRL-1 signalling. Given the epithelial expression of LL-37, it may contribute to the local protection against HIV-1 infection.
Keywords: Antimicrobial peptide, cathelicidin, innate immunity, HIV-1, LL-37, FPRL-1
Current HIV Research
Title: The Antimicrobial Peptide LL-37 Inhibits HIV-1 Replication
Volume: 5 Issue: 4
Author(s): Peter Bergman, Lilian Walter-Jallow, Kristina Broliden, Birgitta Agerberth and Johan Soderlund
Affiliation:
Keywords: Antimicrobial peptide, cathelicidin, innate immunity, HIV-1, LL-37, FPRL-1
Abstract: The antimicrobial peptide LL-37 is the only cathelicidin that has been described in humans. LL-37 exerts chemotactic, immunomodulatory and angiogenic effects; activities that are mediated through binding to the formyl peptide receptor like (FPRL)-1 receptor. Agonistic ligation of FPRL-1 can also induce down-regulation of HIV-1 chemokine receptors and reduce susceptibility to HIV-1 infection in vitro. Therefore, we have evaluated the capacity of LL-37 to inhibit HIV-1 infection in vitro. Here we demonstrate that LL-37 inhibits HIV-1 replication in PBMC, including primary CD4+ T cells. This inhibition was readily reproduced using various HIV-1 isolates without detectable changes in the target cell expression of HIV-1 chemokine receptors. Accordingly, the HIV-1 inhibitory effect was shown to be independent of FPRL-1 signalling. Given the epithelial expression of LL-37, it may contribute to the local protection against HIV-1 infection.
Export Options
About this article
Cite this article as:
Peter Bergman , Lilian Walter-Jallow , Kristina Broliden , Birgitta Agerberth and Johan Soderlund , The Antimicrobial Peptide LL-37 Inhibits HIV-1 Replication, Current HIV Research 2007; 5 (4) . https://dx.doi.org/10.2174/157016207781023947
DOI https://dx.doi.org/10.2174/157016207781023947 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tetraplex Binding Molecules as Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery Omega-3 Nutrition Therapy for the Treatment of Diabetic Sensorimotor Polyneuropathy
Current Diabetes Reviews Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors
Current Pharmaceutical Biotechnology Long-Term Exposure to Ambient Hydrocarbons Increases Dementia Risk in People Aged 50 Years and above in Taiwan
Current Alzheimer Research Cranberry as Promising Natural Source of Potential Anticancer Agents: Current Evidence and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Specific Antidotes in Development for Reversal of Novel Anticoagulants: A Review
Recent Patents on Cardiovascular Drug Discovery Complement C4A and C4B Gene Copy Number Study in Alzheimer's Disease Patients
Current Alzheimer Research Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry One-Step Synthesis of 1H-1,2,3-Triazol-1-Ylmethyl-2,3-Dihydronaphtho[1,2-b]furan- 4,5-Diones
Current Organic Synthesis Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability
Current Drug Metabolism Role of the Hsp90-Immunophilin Heterocomplex in Cancer Biology
Current Cancer Therapy Reviews Synthesis and Biological Applications of Triazole Derivatives – A Review
Mini-Reviews in Organic Chemistry Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design Recent Developments in Nanomedicines for Management of Various Health Issues Via Metabolism and Physico-Chemical Properties
Current Drug Metabolism Clinical Significance of Thiopurine S-Methyltransferase Gene Polymorphisms
Current Pharmacogenomics Recent Developments of Magnetic Nanoparticles for Theranostics of Brain Tumor
Current Drug Metabolism Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives
Current Vascular Pharmacology Drug Delivery Systems for Prevention and Treatment of Osteoporotic Fracture
Current Drug Targets Are Viruses and Parasites Linked to Celiac Disease? A Question that Still has no Definite Answer
Current Pharmaceutical Biotechnology Nanostructures and Substituent Alkyl Chains Effect on Assembly of Organogels Based on Some Glutamic Acid Diethyl Ester Imide Derivatives
Current Nanoscience